{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:38:42Z","timestamp":1773333522052,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,1,12]],"date-time":"2012-01-12T00:00:00Z","timestamp":1326326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:styled-content>Objectives<\/jats:styled-content>: The SPIRIT Small Vessel (SV) was designed to evaluate the safety and effectiveness of the 2.25\u2010mm XIENCE V everolimus eluting coronary stent system (EECSS), known as the XIENCE nano EECSS, in subjects with SVs and ischemic heart disease. <jats:styled-content>Background<\/jats:styled-content>: The core sizes of XIENCE V EECSS are associated with low rates of restenosis and thrombosis in the general population, but the XIENCE nano EECSS has not been tested in the United States. <jats:styled-content>Methods<\/jats:styled-content>: This prospective, single\u2010arm, open\u2010label study was conducted at 33 centers and in 150 patients in the United States. The primary endpoint was the target lesion failure (TLF) rate at 1 year, required to meet the prespecified performance goal (PG) of 20.4%, derived from historical data. <jats:styled-content>Results<\/jats:styled-content>: The mean patient age was 63 years, 38% were women, 39.2% were diabetic, 49.3% had multivessel disease, and the reference vessel diameter was 2.13 \u00b1 0.23 mm. The 1\u2010year TLF rate was 8.1% in with an upper limit of the one\u2010sided 95% confidence interval of 13.0%, which met the PG of 20.4% (<jats:italic>P<\/jats:italic> &lt; 0.0001). At 1 year, the rate of cardiac death was 1.5%, the target vessel myocardial infarction rate was 1.5%, and clinically indicated target lesion revascularization rate was 5.1%. The 8\u2010month angiographic in\u2010stent late loss was 0.2 \u00b1 0.4 mm, respectively. The 1\u2010year academic research consortium defined definite\/probable stent thrombosis rate was 1.5%. <jats:styled-content>Conclusions<\/jats:styled-content>: Based on the 1\u2010year clinical and 8\u2010month angiographic SPIRIT SV data, the XIENCE nano EECSS is considered safe and effective in the treatment of SVs. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ccd.23397","type":"journal-article","created":{"date-parts":[[2011,11,25]],"date-time":"2011-11-25T06:19:55Z","timestamp":1322201995000},"page":"546-553","source":"Crossref","is-referenced-by-count":32,"title":["The XIENCE nano\u2122 everolimus eluting coronary stent system for the treatment of small coronary arteries: The SPIRIT small vessel trial"],"prefix":"10.1002","volume":"80","author":[{"given":"Louis A.","family":"Cannon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel I.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Kereiakes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"James Fleischhauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco A.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,12]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.10581"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000112572.57794.22"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.1174"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.20907"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.22.2727"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.05.052"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.02.025"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.10.1215"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.601823"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi721"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.16.1903"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2008.09.007"},{"key":"e_1_2_8_15_2","volume-title":"TAXUS ATLAS small vessel and long lesion: First report of nine\u2010month clinical and angiographic results","author":"Turco M","year":"2007"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.06.047"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62127-9"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004130"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV6I8A161"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV7I1A14"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910496"},{"key":"e_1_2_8_22_2","article-title":"Comparison of everolimus\u2010eluting and paclitaxel\u2010eluting stents in patients with acute and stable coronary syndromes: Pooled results from the SPIRIT and COMPARE trial","author":"Planer D","journal-title":"J Am Coll Cardiol Cardiovasc Interv"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.23397","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.23397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T20:07:58Z","timestamp":1697054878000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.23397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,12]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1002\/ccd.23397"],"URL":"https:\/\/doi.org\/10.1002\/ccd.23397","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,12]]}}}